Temazepam

Listed in Anlage III of the Betäubungsmittelgesetz (Narcotics Act) since August 1, 1986.¹⁹ Prescriptions must be written on special narcotic prescription forms, except for preparations containing 20 mg or less per dosage unit.citation needed

Temazepam is classified in Verzeichnis b with its stated exemptions; this is distinct from Swissmedic dispensing category B.

The current eCFR lists Temazepam as a Schedule IV depressant, DEA controlled-substances code 2925, in 21 CFR § 1308.14(c)(54). For Schedule IV controlled substances that are prescription drugs, 21 U.S.C. § 829(b) bars dispensing without a conforming written or oral prescription and limits refills to five within six months. These federal rules do not determine state-specific requirements.

The current Commonwealth Poisons Standard identifies TEMAZEPAM in Schedule 4, marked # and also listed in Appendix D. The Therapeutic Goods Administration defines Schedule 4 as Prescription Only Medicine. The Poisons Standard is given legal effect through state and territory legislation.

The current official RIS consolidated Psychotropenverordnung lists Temazepam in Anlage 1 section 2, covering substances in Annex IV of the UN Convention on Psychotropic Substances. Under § 10, medicines containing psychotropic substances may only be prescribed and dispensed according to medical, dental or veterinary science; pharmacies may not dispense unless the prescription meets § 10(2), and repeat dispensing cannot be ordered for benzodiazepine medicines. Temazepam is also expressly named in § 11a's travel threshold.

The current consolidated Controlled Drugs and Substances Act expressly lists temazepam in Schedule IV, under benzodiazepines. The current Benzodiazepines and Other Targeted Substances Regulations classify Schedule IV benzodiazepines as targeted substances and permit an individual to possess one only when obtained from a practitioner or in accordance with a prescription. Health Canada's Drug Product Database independently identifies the approved TEMAZEPAM product as “TARGETED SUBSTANCES (CDSA IV)”.

The Instituto de Salud Pública publishes the official text of Decreto Supremo N.º 405/83, which expressly includes TEMAZEPAM in its list and states that pharmaceutical products containing the listed drugs or salts have the sale condition Receta Médica Retenida. Decreto Supremo N.º 867 is the psychotropic-substances regulation under Ley N.º 20.000; Decreto Supremo N.º 405/83 establishes the temazepam-specific dispensing condition. Temazepam products are available only by prescription, not through unrestricted supply.

Temazepam is controlled under the First Schedule Part I dangerous-drug provisions of Cap. 134, which are distinct from the Pharmacy and Poisons Regulations' separate First Schedule terminology. A doctor may possess, supply or use temazepam only in the course of professional practice. Dangerous drugs are prescription medicines supplied through a registered pharmacy under a registered pharmacist, with additional licensing and record controls. The current Drug Office notice reports no registered temazepam product. The prescription-only classification describes the legal route for an authorized medicinal product or professional possession; it does not indicate current availability for ordinary retail dispensing.

Temazepam is a Schedule 3 controlled drug under Ireland's Misuse of Drugs Regulations 2017. The Regulations prohibit production, supply, importation, and exportation of a controlled drug except as authorised, and permit possession of Schedule 3 drugs for medical purposes only in accordance with a practitioner's directions. Schedule 3 controlled-drug prescriptions must comply with the prescribed form and supply conditions, including the 14-day supply window in Regulation 16.

Temazepam is expressly listed in Lijst II annexed to the Dutch Opiumwet. Dutch CBG medicine records identify authorised temazepam products as UR; CBG defines UR as dispensing only on prescription. Authorised medicines are available only by prescription, while temazepam remains classified under Opiumwet List II; the statutory List II prohibitions do not constitute a general ban on authorised medical supply.

Temazepam is listed as a Class C controlled drug in Schedule 3, Part 5 of New Zealand's Misuse of Drugs Act 1975. Medsafe identifies temazepam with the benzodiazepines as Class C5 controlled drugs and states the associated maximum prescription duration and dispensing controls. Temazepam is available by prescription as a controlled drug rather than through unrestricted supply.

Temazepam is classified under Table IV and is prescription-only.

The current schedule lists Темазепам in List III. The WHO International Nonproprietary Names source lists temazepam under the -azepam stem for diazepam derivatives; Темазепам is the Cyrillic name for temazepam. Federal Law No. 3-FZ permits List III circulation for medical and specified statutory purposes, and requires prescription dispensing for List III substances. Ministry of Health Order No. 1094n specifies prescription form 148-1/u-88 for psychotropic List III medicines. Resolution No. 1002 gives temazepam significant, large and especially large quantities of 1 g, 5 g and 1000 g for Criminal Code Articles 228, 228.1, 229 and 229.1. Unauthorized possession or other conduct can therefore have administrative or criminal consequences depending on the charged conduct and quantity; applicable penalties are statutory ranges or maxima, not case-specific outcomes.

Temazepam is a Third Schedule poison under Singapore's Poisons Rules. Rule 15 requires Third Schedule substances to be sold only upon a prescription given by a medical practitioner, dentist, or veterinary surgeon. The Rules also impose prescription and dispensing requirements, so temazepam is not available for ordinary non-prescription supply.

Temazepam is listed in Schedule 5 as a specified Schedule 5 substance because the official schedule prints Temazepam**. Under section 22A(5)(b), a Schedule 5 substance may be sold by a pharmacist, pharmacist intern or pharmacist's assistant under a pharmacist's supervision on a written prescription from an authorised prescriber or on qualifying verbal instructions from an authorised prescriber known to the pharmacist; Schedule 22A(6) conditions include recording prescribed sale particulars, repeat limits and emergency supply rules. General Regulations 33 requires prescription particulars including prescriber, patient, medicine name, dosage form, strength, quantity, directions and repeats; regulation 35 requires a permanent record for Schedule 5 sales and five-year retention; regulation 36 requires a five-year register for specified Schedule 5 substances held or sold by the listed licensees and sellers. Contravention of section 22A is an offence under section 29(k), and section 30(1) provides a fine or imprisonment for up to 10 years. SAHPRA's current page identifies a Consolidated Schedules (July 2026) version updated 06/07/2026, but its linked SharePoint file returned HTTP 403; the official Government Gazette 54627 (8 May 2026) notice is image-only. The official 01 August 2025 consolidation lists Temazepam**, and SAHPRA labels it archived and DO NOT USE. The current 2026 portal and Gazette do not establish whether the Temazepam** designation changed after the 01 August 2025 consolidation. The schedule does not address product-specific registration, strength, dosage form, import permit status, or any later 2026 schedule change.

The current schedule identifies temazepam exactly and assigns Swedish list IV and international P IV. HSLF-FS 2021:75 defines a narcotic medicine by reference to LVFS 2011:10, requires prescription medicines to be prescribed for outpatient-pharmacy dispensing, authorizes physicians to prescribe medicines for human treatment, and limits exceptional telephone prescribing of list-IV narcotics to the smallest package and no more than 30 divided doses. Läkemedelsverket's narcotics guidance states the personal prescription-and-pharmacy channel and that other use, possession, and purchase are punishable. Under Narkotikastrafflag (1968:64), unauthorized transfer, manufacture, certain dealings, possession, or use is punishable by up to three years' imprisonment; minor offences carry fines or up to six months, gross offences two to seven years, and exceptionally gross offences six to ten years.

Thai FDA guidance is dated 21 September 2024, and the FDA page links a July 2025 list.

Temazepam is listed as a psychotropic substance in Table III, List No. 2 of Ukraine's controlled-substances list. Under the Law of Ukraine on narcotic drugs, psychotropic substances and precursors, citizens may acquire psychotropic substances in Tables II and III only on a doctor's prescription. The substance is therefore lawfully available only through the controlled medical-supply framework, rather than for ordinary non-prescribed possession.

Current legislation.gov.uk text places Temazepam in Part III (Class C drugs) of Schedule 2 to the Misuse of Drugs Act 1971. The current Schedule 3 to the Misuse of Drugs Regulations 2001 expressly names Temazepam and states that Schedule 3 drugs are subject to regulation 15. Regulation 15 applies controlled-drug prescription-form requirements to drugs other than Schedules 4 and 5. S.I. 2015/891 removed the former Temazepam exception from regulation 15 and from the Schedule 3 heading.